MASAC Issues Five New Documents
The National Hemophilia Foundation’s (NHF) Medical and Scientific Advisory Council (MASAC) issued the following new documents, adopted by NHF’s Board of Directors in June 2014.
MASAC Document #224
MASAC Recommendations for the Treatment of Chronic HCV Infection in Individuals with Hemophilia and Other Bleeding Disorders considers the rapid evolution of HCV treatment in light of newly approved oral noninterferon regimens.
MASAC Document #225
MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders encompasses the council’s most recent series of treatment recommendations, including information on currently available therapies.
MASAC Document #226
MASAC Recommendations Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission focuses on the safety and the potential for greater availability of recombinant factor therapies.
MASAC Document #227
MASAC Resupply of factor product in light of limitations imposed by insurance companies and Medicaid.
MASAC Document #228
MASAC Recommendations Regarding the Use of Various Clotting Factor Assays to Monitor Factor Replacement Therapy acknowledges the variabilities and disparate results associated with the use of certain assays and labs in which they are conducted.
Review these and other current MASAC documents. To request a hard copy of any current documents, please call 1.800.424.2634 or email HANDI specialists, who are on call to answer questions and provide information for families and clinicians. The NHF/Novo Nordisk HANDI Library houses the largest resource in the world for materials on bleeding disorders.